DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactSector

Nifty Pharma Today: Index Performance, Stocks & Analysis

Univest 20 hrs ago·13 Aug 2026, 10:34 am

The Nifty Pharma index is currently experiencing a period of consolidation, with key stocks showing mixed performance. The broader market sentiment is cautious as investors weigh the impact of recent regulatory changes and global trends on the sector.

For investors, this phase highlights the importance of sector diversification. While some pharmaceutical companies are posting steady growth, others are facing headwinds. This volatility underscores the need for a balanced portfolio strategy to manage risk effectively.

Moving forward, market participants should closely monitor upcoming earnings reports and government policy announcements. These factors will be critical in determining the sector's short-term direction and identifying potential investment opportunities.